Table 3.
Determination of solution concentrations and metallodrug update associated with specific toxicological endpoints. LD50 was determined by metal equivalent analysis of Pt and Ru for cisplatin and PMC79, respectively. The LC50 concentrations for PMC79 were analytically determined. However, analytical determination of nominal cisplatin concentrations was not conducted; given the known stability of cisplatin in solution, it was assumed that nominal and measured concentrations in solution would be equivalent. The delayed hatching endpoint for cisplatin exposure was evaluated in terms of EC50/ ED50 and LOAEL. The LOAEL concentrations of PMC79 were analytically determined. The LOAEL included lesions such as hemorrhaging along the caudal vein and tail artery, spinal curvature, and yolk sac edema. All 95% Confidence Intervals (CI) were calculated using the Litchfield Wilcoxon method. LC50/LD50: lethal concentration/dose for 50% of treated organisms; EC50/ED50: effective concentration/dose for 50% of treated organisms; LOAEL: lowest observed adverse effect level.
| Dose Response Data | ||||||
|---|---|---|---|---|---|---|
| Cisplatin | PMC79 | |||||
| Nominal (mg/L) | μM | Pt (ng) / organism | Analytical Ru (mg/L) | μM | Ru (ng) / organism | |
| LC50/LD50: | 31 95% CI: (20.5–34.0) |
158 95% CI: (105–174) |
193 (± 130) | 0.79 95% CI: (0.43–1.20) |
7.8 95% CI: (4.2–11.8) |
NA |
| EC50/ED50: | 5 | 12.5 | 22 95% CI: (11–30) |
NA | NA | NA |
| LOAEL | 3.75 | 15.3 | 8.7 (± 4) | 0.17 (± 0.06) | 1.7 (± 0.6) | 0.19 (± 0.05) |